Federal Circuit affirms Merck ‘unclean hands’ verdict

The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US Supreme Court refuses to hear appeal against ‘unclean hands’ decision

10 January 2019 The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.

Americas

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Americas

Judge overturns $200m award in Gilead v Merck

9 June 2016 A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Federal Circuit affirms Merck ‘unclean hands’ verdict

More on this story

Editor's picks

Editor's picks

More features